An AllTrials project

NCT04209855: An ongoing trial by ImmunoGen, Inc.

This trial is ongoing. It must report results 7 months, 1 week from now.

Full data

Full entry on ClinicalTrials.gov NCT04209855
Title MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Dec. 31, 2019
Completion date Sept. 30, 2023
Required reporting date Sept. 29, 2024, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov Feb. 9, 2024
Days late None